Generic Name: bezlotoxumab
Date of Approval: October 21, 2016
Company: Merck & Co., Inc.
Treatment for: Prevention of Clostridium Difficile Infection Recurrence
FDA Approves Zinplava
The U.S. Food and Drug Administration (FDA) has approved Zinplava (bezlotoxumab), a monoclonal antibody indicated to reduce recurrence of Clostridium difficile infection (CDI) in adults who are receiving antibacterial drug treatment of CDI and are at high risk for CDI recurrence.
Read this Patient Information before you start treatment. This information does not take the place of talking with your healthcare provider about your medical condition or your treatment.
Before you start treatment
Before you receive this medicine, be sure you understand what it is for and how it is given.
- Zinplava helps decrease the risk of C-diff (Clostridium difficile infection) from coming back by working with the antibiotic that you are taking to treat your C-diff. It is not an antibiotic and does not replace the antibiotic.
- Keep taking your antibiotic for your C-diff as directed by your doctor.
- If you have questions about your treatment, ask your doctor or pharmacist.
What is Zinplava?
Zinplava is a prescription medicine used to help decrease the risk of C-diff from coming back in people 18 years of age or older who are taking an antibiotic for C-diff and who have a high risk of C-diff coming back.
C-diff is a bacterial infection that can damage your colon and cause stomach pain and severe diarrhea. When people get C-diff, they often take an antibiotic to get rid of the infection. Even when treated by an antibiotic, C-diff can come back within weeks to months. Zinplava helps to decrease the risk of the infection from coming back. It works when given along with the antibiotic that you are taking to treat C-diff.
How will I receive Zinplava?
- You will receive this medicine via your vein through an IV (intravenously).
- You do not need to do anything to prepare for receiving your treatment.
- You will receive the injection in one dose and it will take about one hour.
- If you miss your appointment, call your doctor right away to reschedule it.
- It is not known if this medicine is safe and effective in children under 18 years old.
- If you are pregnant or trying to get pregnant, tell your doctor. It is not known if this medicine will harm your baby while you are pregnant. You and your doctor should decide together if you will receive Zinplava.
- If you are breastfeeding or plan to breastfeed, tell your doctor. It is not known if this medicine gets in your breast milk and will be passed to your baby. You and your doctor should decide together if you will receive Zinplava.
- Tell your doctor about any medical conditions you have now or have had before.
- Make sure to tell your doctor if you have or have had congestive heart failure (CHF).
- Tell your doctor about all of the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
Zinplava side effects
Serious side effects include:
- Heart failure. Heart failure may happen in people who receive this medicine, and can be serious. People with a history of congestive heart failure (CHF) who received Zinplava had a higher rate of heart failure and death than those who did not.
Common side effects that may happen on the day of or the day after receiving Zinplava include:
- feeling tired
- shortness of breath
- feeling dizzy
- high blood pressure
Common side effects that may happen up to four weeks after receiving Zinplava include:
If you have any side effect that bothers you or does not go away, tell your doctor.
There may be other side effects that are not listed above. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Medicines are sometimes prescribed for purposes other than those listed in the Patient Information. You can ask your pharmacist or doctor for information about that is written for doctors.
What are the ingredients?
Active ingredient: bezlotoxumab
Inactive ingredients: citric acid monohydrate, diethylenetriaminepentaacetic acid, polysorbate 80, sodium chloride, sodium citrate dihydrate, and water for injection, USP. Zinplava may also contain sodium hydroxide.